BMS:Pfizer

Information intended for UK healthcare professionals only.   These promotional videos have been funded by Bristol Myers Squibb on behalf of the BMS / Pfizer Alliance and developed in conjunction with Guidelines. See bottom of the page for full disclaimer.

View ELIQUIS (apixaban) prescribing and adverse event reporting information

In these videos Dr Yassir Javaid  (Cardiovascular and Diabetes Lead Nene CCG; Primary Care Cardiovascular Lead, East Midlands Clinical Network; RCGP Clinical Adviser for Cardiology) and Dr Derek Connolly  (Consultant Interventional Cardiologist, Sandwell and West Birmingham NHS Trust) summarise the main messages covered in the live webinar ’The impact of DOACs on stroke in patients with NVAF: practical considerations for those with comorbidities’, broadcast on 29 September 2021.

Risk assessment for stroke prevention in NVAF

NVAF and comorbidities

Anticoagulation in NVAF patients with comorbidities

The impact of DOACs on stroke in NVAF patients: practical considerations for those with comorbidities—Q&A session

These videos are best viewed in full screen mode.

Risk assessment for stroke prevention in NVAF

NVAF and comorbidities

 Anticoagulation in NVAF patients with comorbidities

The impact of DOACs on stroke in NVAF patients: practical considerations for those with comorbidities—Q&A session

 

DOAC=direct oral anticoagulant; NVAF=non-valvular atrial fibrillation.

Adverse events should be reported. Reporting forms and information can be found at: UK – www.mhra.gov.uk/yellowcard, or search for MHRA Yellow Card in the Google Play or Apple App Store Adverse events should also be reported to Bristol-Myers Squibb via medical.information@bms.com  or 0800 731 1736 (UK)

These promotional videos have been funded by Bristol Myers Squibb on behalf of the BMS / Pfizer Alliance and developed in conjunction with Guidelines.   Bristol Myers Squibb has reviewed the scope of the videos, chosen and commissioned the speakers, and approved all materials related to the videos. Bristol Myers Squibb has paid the speakers honoraria. The views and opinions of the speakers are not necessarily those of Guidelines, its publisher, advisers, or advertisers. No part of these videos may be reproduced in any form without the permission of the publisher.

432-GB-2100966

Date of preparation: January 2022